GlassScriptPhysician profile
Quinta E Tangoh
NPI 1871188367
$6,679.30
in general payments reported to CMS, 2019-2025
21 companies · $1,048 in 2025
The $1,048 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,628 · 2022: $1,870 · 2023: $1,015 · 2024: $1,118 · 2025: $1,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,180.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,144.66 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $984.97 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $927.12 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $808.32 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $740.91 | 2021-2025 | Caplyta |
| Lundbeck LLC | $528.66 | 2021-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $340.96 | 2021-2022 | |
| Indivior INC. | $200.89 | 2022-2024 | Sublocade |
| Vanda Pharmaceuticals INC. | $172.16 | 2021-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $165.57 | 2023-2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $131.88 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $125.00 | 2025 | Qelbree |
| Braeburn INC. | $108.67 | 2024-2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $80.54 | 2021-2023 | Vyvanse, Trintellix |
| Teva Pharmaceuticals USA, INC. | $50.63 | 2024 | Uzedy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.10 | 2022-2024 | |
| Corium, LLC | $36.54 | 2022 | |
| Tempus Ai, INC | $35.15 | 2024 | |
| Orexo US, INC. | $20.44 | 2024 | Zubsolv |
| Neuronetics, INC. | $19.30 | 2022 | |
| Noven Therapeutics, LLC | $16.83 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quinta Tangoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.